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Abstract Antigen-specific immune responses in multiple
sclerosis have been studied for decades, but the target
antigens of the putatively autoaggressive B and T cells still
remain elusive. Here, we summarize recent strategies which
are based on the direct analysis of biopsy or autopsy
specimens from patients. Since this material is extremely
scarce, the experimental methods need to be exceptionally
sensitive. We describe technologies to distinguish (auto)
aggressive T cells from irrelevant bystander lymphocytes
by analyzing clonal expansions in relation to the morpho-
logical location of the cells in the tissue lesions. We then
discuss approaches to clone matching α- and β-chains of
the antigen-specific T cell receptor (TCR) molecules from
single T cells. This is necessary because usually, several
clones are expanded and are diluted by many irrelevant
cells. The matching TCR chains from individual T cells can
be resurrected in hybridoma cells which may then be used
for antigen searches. We discuss strategies to identify
antigens of γδ- and αβ-TCR molecules, such as biochem-
ical methods, candidate antigens, human leukocyte antigen
requirements, synthetic peptide, and cDNA libraries. These
strategies are tailored to characterize the antigens of the
membrane-anchored, low-affinity TCR molecules. The
strategies to identify (auto) reactive B cells or immuno-
globulin (Ig) molecules are fundamentally different, be-
cause Ig molecules are water-soluble and have high
affinities. We further discuss proteome-based approaches,
techniques that analyze Ig-chains from single B cells, and a
repertoire-based method that compares Ig-proteomes and
Ig-transcriptomes. The first method detects Ig antigens
directly, whereas the latter two methods allow reconstruc-
tion of Ig molecules, which can be used for antigen
searches.
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Introduction
The current concepts of multiple sclerosis (MS) as an
autoimmune disease are mainly based on the animal model
“experimental autoimmune encephalomyelitis” (EAE) [1,
2]. In different EAE models, several distinct molecularly
defined antigens could be demonstrated to induce patho-
genic T and/or B cell responses. However, the target
antigen(s) recognized by immune cells in the different
forms of human MS still remain speculative. In the past,
most investigations of putatively pathogenic human B- and
T cells relied mainly on blood as the most easily accessible
source. Obviously, this is far from ideal, because any
relevant cells are (a) remote from the target tissue, (b)
heavily diluted with irrelevant cells, and (c) likely to have
phenotypical and functional properties completely different
from the tissue-infiltrating cells. Most importantly, all
investigations of isolated circulating or migrating cells
necessarily lack crucial morphological information on how
the cells interact with the surrounding tissue. The most
direct approach would of course be to focus on the
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information. This approach is far from trivial, because it
demands a set of new techniques for obtaining maximum
information from scarce human autopsy and biopsy
material.
The central problem of such a direct strategy is the
availability of tissue samples. For most diseases, well-
preserved biopsy specimens are extremely rare. For
example, brain or spinal cord lesions are usually not
biopsied in MS patients. The same holds true for pancreas
samples of type I diabetes patients, etc. There are only few
autoimmune diseases where diagnostic biopsies are taken
on a regular basis. One such example is provided by the
inflammatory myopathies (IM). This situation contrasts
with animal experiments, where diseases may be induced
and manipulated experimentally, and where tissue samples
may be collected at any time point of choice, even at pre-
clinical stages.
For many years, we have investigated antigen-directed
immune responses in MS and IM target tissues, that is,
brain and muscle. Both in MS and IM, T cells—especially
CD8+ cells—infiltrate the organs. It is not known how
these cells are attracted or how the local inflammatory
response is sustained. The target antigens are also
unknown. The B cell responses, i.e., the (auto) antibody
responses, are somewhat better understood. This is mainly
due to the fact that soluble immunoglobulin (Ig) proteins
are easier to investigate than autoaggressive T cells where
the autoaggressive T cell receptor (TCR) is a member of a
multimeric complex of membrane proteins. During the
course of our studies, we have developed a series of
technologies that allow analysis of T and B cell responses
in IM and MS.
Our main long-term goal is to identify the target antigens
recognized by tissue-infiltrating T and B cells in MS and
IM [3]. With very few exceptions, these target antigens are
unknown. This is unfortunate, because knowing the target
antigens would be of great help for developing diagnostic
markers and immunotherapies. To achieve this goal, many
obstacles need to be overcome: Firstly, well-preserved
tissue, especially brain biopsy material, is very rare.
Secondly, putatively autoreactive T cells and B cells must
be distinguished from bystander cells (Fig. 1). Therefore,
morphological analysis followed by microdissection and
single cell polymerase chain reaction (PCR) is required,
which is, thirdly, particularly difficult owing to the
extremely low RNA concentrations. Fourthly, the antigen-
specific TCR and Ig molecules are both composed of
various genetic elements, containing hypervariable regions
and mutations. Therefore, multiplex PCR must be
employed. Fifthly, the search for antigens is not trivial
because huge libraries must be screened. This is particularly
difficult for Tcells, because the notoriously low affinities of
TCR-antigen interactions [4–7] impede straightforward
biochemical methods.
The first step of our analysis is the identification of cell
clones or Ig molecules that are expanded in the target
tissue, driven by antigen recognition. Such “repertoire
studies” help us to distinguish between pathogenic and
irrelevant cells or molecules. In the next step, we focus on
individual T cells and their antigen-specific receptor, or on
clonally expanded antibodies. We then amplify the TCR or
Ig chains by PCR and express them in vitro. The trans-
fectants are then used for antigen searches. In a first series
of experiments, “best guess” candidate antigens may be
screened. Such candidates usually come from animal
experiments. A more unbiased approach is to screen cDNA
expression libraries. The cDNA libraries may be generated
from the affected organs, or—preferred—from the biopsy
specimen of the patient. Depending on whether B or T cell
antigens are investigated, the libraries are either expressed
and screened directly or must be introduced into the class-I
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Fig. 1 Autoaggressive T cells attack muscle fibers. In the schematic
representation (left) the autoaggressive T cells are shown in red. Many
other bystander T cells and T cells in blood vessels are present in the
same tissue (blue and green). On the right panel, we show an
immunohistochemical stained cryosection from the muscle of a PM
patient. CD8+ T cells are stained in green. In the scheme and in the
cryosection, muscle-attached single T cells and T cell clusters that
focally invade the muscle fibers are seen (modified from [23] with
permission)
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sentation pathway before they are screened.
Here, we will review the current state of antigen
detection efforts in MS research. Both, for B cell and for
T cell antigens, several technical challenges have to be
overcome. Since the experimental strategies for identifying
B and T cell antigens are quite different, we will discuss the
respective approaches separately. Needless to say, these
new techniques may also be applied to tissues from patients
with other autoimmune, neoplastic, or inflammatory dis-
eases where adaptive immune responses occur.
T cell antigens
TCR repertoire in autoimmune tissue lesions
Tissue-infiltrating T cells are observed in all patients with
MS or IM. In most cases, the T cell infiltrates are composed
of αβ-T cells, whereas γδ-T cells are rather an exception
[8–10]. In MS, CD8+ T cells usually outnumber the CD4+
population [11]. In IM, it depends on the subtype of the
disease: While in inclusion body myositis and polymyosi-
tis, CD8+ T cells clearly dominate, while CD4+ T cells are
more prominent in dermatomyositis [12, 13]. We have
intensively studied the αβ-TCR repertoire of infiltrating
CD8+ T cells in MS brain specimens [14–16] and in
myositis muscle tissue of polymyositis and inclusion body
myositis patients [17–19]. Using CDR3-spectratyping, we
found that in these diseases, CD8+ T cells are expanded in
the target tissues and blood, and that these expanded clones
may persist for many years in some patients. We investi-
gated the TCR repertoire in muscle samples and blood of
several patients with IM [19] and in brain tissue, cerebro-
spinal fluid (CSF), and blood of MS patients [15]. In the
myositis study, we identified expanded T cell clones in
muscle biopsy tissue of ten patients. From four patients, we
isolated single, morphologically characterized T cells by
laser microdissection and analyzed the TCR β-chains
by single cell PCR. These T cells were most probably
autoaggressive, because they belonged to expanded clones,
were in direct contact with their target cells, and carried
silent nucleotide exchanges in the TCR CDR3-N-regions.
This indicates that the clonal expansions were driven by
particular antigen(s). Expanded clones were not only
detectable in muscle tissue but also in the CD8+ T cell
compartment of peripheral blood, where they persisted for
many years. Persistent CD8+ T cell clones were also
detected in MS patients [15]. We found that these CD8+
clones were also present in brain tissue, CSF, and peripheral
blood. By contrast, the CD4+ population was polyclonal.
Strikingly, some of the CD8+ T cells that had been
identified in brain tissue persisted in peripheral blood and
CSF for more than 7 years. These repertoire studies were
the basis of a general strategy that leads to the molecular
characterization of αβ-TCR molecules from autoaggressive
T cell [3].
More recently, we compared the TCR repertoires in
distinct lesions and in “normal appearing white matter”
regions of human autopsy brains from MS patients [16].
Using CDR3-spectratyping, we identified several pervasive
T cell clones in anatomically distant brain lesions, but we
did not find any significant differences between lesions and
normal appearing white matter. Strikingly, we found silent
nucleotide exchanges in some clones, hinting to antigen-
driven clonal T cell selection. By combining immunohisto-
chemistry, laser microdissection, and single cell PCR, we
could attribute some of these clones to the CD8+
population (Fig. 2). Such expanded clones are excellent
candidates for investigating the corresponding TCR α-
chains, which is a prerequisite for subsequent antigen
searches.
This technology is highly valuable not only for investi-
gating T cell expansions in autoimmune diseases but may
also be applied to infections and tumors. For example, we
detected several expanded CD8+ T cell clones in herpes
simplex virus-infected human trigeminal ganglia, pointing
to an antigen-driven immune response [20]. Furthermore,
we identified identical T cell clones in tumor tissue and in
CSF of a patient with paraneoplastic encephalomyelitis.
Notably, silent nucleotide exchanges in the CDR3-N-region
suggested that the T cell response in the tumor and in the
nervous tissue was directed against a shared antigen,
linking the (protective) anti-tumor response and the
(adverse) paraneoplastic response against nervous tissue
[21]. Further, we identified expanded CD8+ T cell clones in
brain specimens of patients with Rasmussen encephalitis
suggesting antigen-driven proliferation [22].
Identification and in vitro “resurrection”
of tissue-infiltrating T cells
In most cases, it is virtually impossible to obtain viable
autoaggressive T or B cells from biopsy specimens. The
first obvious reason is that most available biopsy samples
are stored frozen and therefore contain only dead cells.
Even if it were possible to obtain a biopsy sample directly
after its excision, it would be very difficult to distinguish in
the fresh tissue the putatively autoaggressive T cells from
cells that were attracted as bystanders or are present in
blood vessels near the inflammatory lesion (Fig. 1). To
distinguish between relevant and irrelevant cells, it would
be necessary to stain for activation markers and to apply
morphological criteria. Next, it would be very difficult to
isolate single living cells from such a tissue specimens and
to subsequently expand them at a large scale. Such
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cells are required to screen the huge libraries for antigen
detection (see below). In summary, it will only be possible
under exceptional circumstances to use “real” T or B cells
directly from tissue of patients with autoimmune diseases.
The situation may be different in some tumors, where big
tissue samples are more readily available.
A feasible alternative is the recombinant expression of
the antigen-specific receptors that were detected “at the
crime scene” in a frozen tissue sample. Based on the
repertoire studies described above, we have developed an
experimental strategy allowing us to identify paired TCR
α-a n dβ-chains from single cells isolated by laser
microdissection from cryosections (Fig. 3)[ 23]. Detection
of TCR α-chains has previously been difficult, because
TCR α-chain genes contain more elements than β-chain
genes [24], and because only very few anti-α-chain
antibodies are available for immunohistological staining.
We distinguish putatively autoaggressive T cells from
irrelevant bystander cells by two criteria: First, we screen
for clonally expanded TCR β-chains by CDR3-
spectratyping, because we assume that putatively autoag-
gressive populations are expanded in situ. Second, we
identify T cells showing morphological features of autoag-
gressive behavior by immunohistochemistry. Since we
know from the CDR3-spectratyping experiments which
TCR β-chains are expanded in situ, we use antibodies that
recognize this particular Vβ-region. Candidate cells that
fulfill both criteria are isolated by laser microdissection. To
identify matching α-a n dβ-chains, we apply a new
multiplex PCR protocol which allows the unbiased ampli-
fication of both TCR chains from single T cells isolated
from cryosections. The first step is to confirm that the cell
under question not only carries the correct Vβ-element but
also the correct N(D)N- and J-sequences. To this end, we
amplify the TCR β-chain cDNA using clone-specific
primers based on the sequences identified by spectratyping.
If such a relevant sequence can be confirmed, we detect the
matching α-chain using a universal α-primer set that allows
amplification of every possible α-chain. Such a multiplex
PCR is of course not as sensitive as a PCR reaction with
clone-specific primers. Therefore, we re-examine all β-
chain positive T cells where no α-chain has initially been
detected with the universal primer set. For this additional
screen, we use highly efficient clone-specific primers that
Fig. 2 Some of the expanded T
cells clones in the brain tissue of
multiple sclerosis patients be-
long to the CD8+ compartment.
We detected expanded T cell
clones by CDR3-spectratyping
and sequencing of the polymer-
ase chain reaction products
(upper panel). Identical sequen-
ces were detected in single T
cells that were stained by anti-
CD8-antibodies and isolated by
laser microdissection from cry-
osections (lower panel; modi-
fied from [16] with permission)
Fig. 3 Strategy for the identification of the target antigens of tissue-
infiltrating autoaggressive T cells. The protocol may not only be
applied to autoimmune diseases but also to other types of inflamma-
tory lesions, including tumors and transplants (modified from [23]
with permission)
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PCR protocol yields only fragments of the TCR chains, the
full-length clones must next be reconstructed. Although
laborious, this is basically achieved by standard molecular
biology techniques. The reconstructed chains are then
inserted into an expression vector and transfected into the
T hybridoma cell line 58α
−β
− [25, 26] which lacks
endogenous TCR chains but carries all CD3 molecules
and the machinery to secrete interleukine-2 after TCR
stimulation. The transfected cells can then be used to search
for the antigens. Thus, we have essentially “revived” the
putatively autoaggressive T cells that were originally
observed in “dead” tissue [23]. In the meantime, we have
successfully applied this technology not only to polymyo-
sitis and inclusion body myositis but also to MS and other
diseases.
So far, we have identified one γδ- and eight αβ-TCRs
from muscle biopsy specimens of myositis patients. We
started these studies with samples from myositis patients,
because diagnostic tissue specimens were readily available.
In one patient, we found four structurally closely related α-
chains associated with identical β-chains. One of the α-
chains was found much more often than the others
indicating a dominant expansion. Recently, we have
identified four αβ-TCRs from the brain biopsy sample of
the MS patient who has been studied extensively by single
cell PCR and CDR3 spectratyping [14, 15]. The TCR β-
chain of the four clones is identical. The α-chains have
identical V-regions (which code for two of the three
complementarity determining regions (CDR1 and 2)).
Therefore, five of the six CDR regions which contact the
antigen are identical. Strikingly, the N-regions which code
for the CDR3-region of the four α-chains are different, but
highly homologous. This definitely excludes PCR contam-
inations or cloning artifacts. In one myositis and in one MS
patient, we identified a dominant T cell clone that is
accompanied by several other subdominant clones carrying
structurally closely related TCRs. Although the clones have
an ontogenetically different background, their expansion
m i g h th a v eb e e nd r i v e nb yac o m m o na n t i g e n .T h i s
interpretation is supported by a recent study of clonal T
cell expansions in a patient with a paraneoplastic neuro-
logical disease where, again, ontogenetically different but
structurally identical TCR β-chains were observed in
blood, tumor, and nervous tissue [21].
Strategies for identification of T cell target antigens
gδ-TCR antigens
The first TCR that we revived was a γδ-TCR from a
muscle biopsy specimen of a polymyositis patient [8]. The
unique feature of this case was the monoclonal character of
T cell expansion [27]. This allowed us to clone both TCR
chains by conventional PCR techniques. We expressed the
γδ-TCR on the surface of the T hybridoma cell line
58α
−β
− and used the transfectants for characterization of
the unknown target antigens [28, 29]. Identification of the
target antigens of γδ-TCRs is particularly difficult because
γδ-TCRs are not MHC restricted. Instead, they may
recognize the entire spectrum of chemicals, including low
molecular weight compounds that are immobilized by
proteins [30–33]. Strikingly, the affinity of γδ-TCRs to
their targets is very low. Therefore, biochemical methods
such as immunoprecipitation or affinity chromatography,
which are most efficient for detecting the ligands of Ig or
receptors (except TCRs), are not applicable. For this reason,
the protein(s) that present alkyl phosphates to the most
prevalent human γδ-TCR subset, the Vγ9Vδ2 T cells, are
still not known [34]. By classical biochemical methods, we
have gathered a substantial amount of information on the
properties of the target antigen(s): it is expressed in the
cytosol of the target cells, it is water-soluble, has a
molecular mass greater than 8 kDa, and contains a protein
moiety [29]. Most recently, we have gained preliminary
evidence that proteins involved in RNA translation are the
molecular targets of our γδ-TCR. These proteins express a
common motif which is conserved through many species
from man to bacteria. This is consistent with a molecular
mimicry-like mechanism of induction of autoimmunity
([35–37].
ab-TCR antigens: HLA-requirements
and candidate antigens
All αβ-TCR molecules depend on the presentation of
antigenic peptides by their relevant human leukocyte
antigen (HLA) restriction molecule. When a particular
TCR is cloned from a tissue sample, it is a priori not
known which of the HLA molecules of the patient is
required for antigen presentation. For each CD8+ or CD4+
T cell, any one of the six class-I or class-II molecules may
be the correct candidate. Ideally, one would therefore like to
use autologous professional antigen presenting cells (APC)
from the investigated patient. However, even if original
tissue or blood of the patient were available, it would
presumably be difficult to generate sufficient numbers of
autologous dendritic cells, macrophages, or other profes-
sional APCs from such limited sources. As an alternative,
Epstein–Barr virus transformed B cell line may be
generated from the patient’s blood, but such cell lines are
non-adherent, grow in big clusters, and are difficult to
transfect. They are therefore not very well suited as
recipient cells for huge libraries, where a high transfection
efficiency is required. Not many alternatives remain, except
for determining the HLA alleles of the patients by standard
Semin Immunopathol (2009) 31:467–477 471techniques and then co-transfecting them together with
cDNA libraries into immortalized cell lines. This was
indeed the way how the first T cell antigens of tumors
were identified [38]. By contrast, in animals, where tissue
supply is virtually unlimited, things are less complicated:
tissue can be fractionated by biochemical methods and
presented by autologous APCs until the antigen(s) are
finally characterized [39].
In some diseases, there are candidate antigens that may
be tested as a “best guess”. For MS, there are several
candidates, all of which come from the animal model EAE.
Examples include myelin basic protein, proteolipid protein,
myelin oligodendrocyte glycoprotein, S100ß, neurofascin,
neurofilament, and aquaporin-4. Some of them are available
as proteins purified from human brain or as recombinant
proteins. In case of CD4+ T cells, the candidate antigens
may just be added to APCs, which take them up, digest
them in their lysosomes, and present them on their HLA
class-II molecules. In case of CD8+ T cells, things are more
complicated: Peptides or proteins that are added to the cells
from the outside will reach class-I MHC molecules only if
dendritic cells are used as APCs, because dendritic cells are
the only cell type that is capable of cross-presentation [40,
41]. All other cell types direct external antigens almost
exclusively onto class-II MHC molecules. Dendritic cells,
however, are available only in very limited amounts and
can not be expanded into high cell numbers. This
considerably limits their usage. The best way to direct
antigens onto class-I HLA molecules is transfection of their
coding DNA into APCs. To this end, the cDNAs of the
candidate antigens need to be cloned and inserted into a
suitable plasmid or viral vector, which is of course
laborious and time consuming.
ab-TCR antigens: combinatorial peptide libraries
A versatile and efficient method may be the use of
positional scanning synthetic combinatorial peptide librar-
ies (PS-SCL) [42–44]. The idea behind these libraries is
that TCR molecules recognize patterns rather than defined
sequences or structures. In other words, the recognition of
target structures is polyspecific, promiscuous, and degener-
ate [45]. Therefore, it is often observed that some amino
acids of a given peptide may be substituted by chemically
similar amino acids. In some cases, even very different
amino acids may be substituted without loss of TCR
recognition. PS-SCL therefore contain random amino acids
in all but one position of the peptide. The one position that
is fixed is successively occupied with one defined amino
acid. Randomization is achieved by introducing all 20
possible amino acids simultaneously during peptide syn-
thesis. A library of 9mer peptides therefore consists of
9 × 20=180 different randomized peptide pools. For
comparison, synthesis of all possible 9mer peptides would
require 209 ¼ 0:5   1012 different individual peptides.
For evaluation of TCR recognition motifs, the random-
ized peptide pools are presented by appropriate APCs to the
TCRs. In the example given above, 180 tests must be run.
TCR activation will be observed whenever a relevant amino
acid fits to the TCR recognition motif, for example, a
positive charge at position 2, an aromatic amino acid at
position 5, and small amino acids at positions 4 and 9.
Several peptide pools are usually recognized, and altogeth-
er, they provide the TCR recognition motif, which may then
be searched for in databases of existing proteins [43]. The
search may or may not be limited to databases from par-
ticular species, such as human or microbial proteins. Finally,
candidate peptides are synthesized and tested individually.
ab-TCR antigens: cDNA libraries
Since the seminal studies of Van der Bruggen et al. [38], a
number of tumor antigens have been identified by screening
of cDNA libraries [46, 47]. Many studies followed the
original experimental concept where a cDNA library from
tumor tissue was cloned into a plasmid that contained the
SV40 origin of replication. These plasmids were co-
transfected together with the appropriate HLA molecules
into COS cells, where they are amplified and they produce
the putative antigens. The plasmids can be recovered from
positive APCs so that the inserts may be identified by
sequence analysis. An alternative method uses a viral vector
which also allows plasmid recovery and sequence analysis
[48]. Screening of a cDNA library has revealed autoantigens
in a diabetes mouse model [49], but so far, no antigens from
human autoimmune diseases have been identified.
The choice of the library is critical, for which several
alternatives exist. First, tissue-specific libraries may be
generated or purchased from various suppliers. Although
this is the most convenient, the disadvantages are clear:
These libraries do not contain any patient- or disease-
specific peculiarities or polymorphisms. Further, the distri-
bution of transcripts is heavily biased, and rare transcript is
highly diluted. Second, “normalization” of libraries may
overcome the latter disadvantage. Normalization means that
the most abundant transcripts are reduced in number
through a series of hybridization steps. This method
requires high amounts of cDNA to start with and is
technically far from trivial. Third, cDNA may be extracted
from tissue of patients. Such a library would contain all the
patient- and disease-specific polymorphisms (including
viral transcripts), but clearly, such material is scarce. A
further disadvantage is that whole biopsy tissue still
contains many different cell types, not only the cells that
are targeted by the autoimmune attack. A fourth, technically
challenging type of library is the subtraction library. Here,
472 Semin Immunopathol (2009) 31:467–477disease-related transcripts are strongly overrepresented.
Such libraries are generated by cloning only the cDNAs
that are differentially expressed between two tissues. An
excess of RNA from one tissue is immobilized on a solid
surface, cDNA from another tissue is hybridized, and the
non-hybridizing transcripts are collected. They are then
cloned into expression vectors which are used to transfect
suitable APCs. Subtraction libraries require high amounts
of material. Although T7 promoter-based linear RNA
amplification kits [50] are meanwhile available from
several commercial sources, there are still problems
obtaining enough full-length products. Note that for many
applications, such as analysis by microarrays or quantitative
PCR, short, incomplete sequences are often sufficient,
whereas expression cloning requires full-length sequences
with intact, in-frame translation start codons.
B cell antigens
The role of B cells in MS is increasingly appreciated [51].
The search for B cell antigens may be conducted by using
serum samples or other body fluids that contain relatively
high amounts of (auto) antibodies. This is a big advantage
as compared to investigating T cell antigens, because
cloning of Ig chains from single cells is not necessarily
required, although the latter approach might also be an
option. We will discuss here three different approaches to
analyze B cell (auto) antigens: The first is a proteomic-
based strategy where brain tissue is fractionated, the
putative antigens are separated by 2-d gel electrophoresis,
and screened with patient’s sera. This resulted in the
identification of the two axoglial antigens neurofascin and
contactin-2/TAG-1 as novel targets of autoantibodies of MS
patients. Testing the functional relevance of an autoimmune
response against these two novel autoantigens revealed that
antibodies to neurofascin specifically target the node of
Ranvier and induce an axonal injury [52], and that a T
cellular response against contactin-2 induced gray matter
lesions [53]. The second approach is comparable to the
strategy for the identification of putatively autoaggressive T
cells discussed above: single B- or plasma cells are excised
from tissue sections, the Ig chains are analyzed, and
recombinant Ig molecules are used for antigen searches.
The third strategy makes use of the virtually infinite
variability of antibodies that underwent affinity maturation:
Ig-mRNA transcriptomes are established from CSF of
patients and compared to the Ig-proteome, which is
determined independently from the same tissue by mass
spectrometry. This allowed us to match the Ig-transcriptomes
and -proteomes of the so-called “oligoclonal bands” (OCBs)
of MS patients [54]. These experiments provided evidence
that B lineage cells are able to synthesize the OCBs and
allowed us to identify and reconstruct Ig molecules that
constitute the OCBs.
Proteome-based approach
This strategy is based on a separation of different protein
preparations from the brain by 2D gel electrophoresis and
subsequent identification of the proteins that are recognized
by MS patients sera with a subsequent Western blot and
mass spectrometry. To follow this line, we first focused on
myelin glycoproteins as potential targets. This focusing on
glycoproteins has two reasons. First, glycoproteins are
quantitatively minor components, and enrichment of gly-
coproteins greatly enhances the sensitivity for detection of
antibodies against them [53]. Second, glycoproteins are
expected to be largely at the outer surface and should
therefore be easily accessible to antibodies. With this
approach, we could identify the two neuronal-glial antigens
neurofascin and contactin-2/TAG-1 as novel targets of
autoantibodies of MS patients. Neurofascin exists in two
isoforms: NF186 is a neuronal protein concentrated in
myelinated fibers at nodes of Ranvier, and NF155 is the
oligodendrocyte-specific isoform of neurofascin concentrat-
ed at the paranodes. To evaluate whether circulating anti-
neurofascin antibodies mediate a pathogenic effect in vivo,
we co-transferred these antibodies with myelin oligoden-
drocyte glycoprotein-specific encephalitogenic T cells to
mimic the inflammatory pathology of MS and breach the
blood–brain barrier. In this animal model, antibodies to
neurofascin selectively targeted nodes of Ranvier, resulting
in deposition of complement, axonal injury, and disease ex-
acerbation [52]. Together, we have identified a novel mecha-
nism of immune-mediated axonal injury. The relevance for
the axonal pathology in MS needs to be elaborated.
The second novel target of autoantibodies that we could
identify with this approach is contactin-2/TAG-1 [53].
Contactin-2 and its rat homologue TAG-1 (transiently
expressed axonal glycoprotein-1) are expressed by various
neuronal populations and sequestered in the juxtaparanodal
domain of myelinated axons both at the axonal and myelin
side. We found that MS patients mount both autoantibodies
and Th1/Th17 T cell responses specific for contactin-2. The
pathogenic significance of these autoimmune responses was
then explored in EAE models in the rat. Adoptive transfer
of TAG-1 specific T cells induced an encephalitis charac-
terized by a preferential inflammation of gray matter of the
spinal cord and cortex. Co-transfer of TAG-1-specific T
cells with a myelin oligodendrocyte glycoprotein-specific
mAb generated focal perivascular demyelinating lesions in
the cortex and extensive demyelination in spinal cord gray
and white matter. This study identifies contactin-2 as a
novel autoantigen targeted by T cells and autoantibodies in
MS. Our findings suggest that a contactin-2-specific T cell
Semin Immunopathol (2009) 31:467–477 473response contributes to the development of gray matter
pathology.
B cell-based approach
Similar to the analysis of single Tcells, strategies have been
developed to analyze antibodies produced by single cells of
the B linage. Again, the morphology of the tissue lesion is a
main criterion to discriminate between irrelevant and
potentially relevant cells, and therefore, again, multiplex
single cell analysis is required. A number of protocols for
amplification of matching heavy and light chain cDNA
from single B- or plasma cells have been described [55–
59], and many expression systems are suited to produce
recombinant single-chain Fv molecules, Fab fragments, or
whole antibodies for a variety of purposes [60]. However,
no antigens have so far been identified that are recognized
by antibodies detected in single B- or plasma cells isolated
from brain or muscle specimens [61–63]. This is particu-
larly surprising because most Ig chains amplified from
tissue lesion are of the IgG1 family and contain many
somatic hypermutations. Therefore, they should bind their
antigens with relatively high affinity. This would be a major
prerequisite for employing established antigen identifica-
tion techniques such as immunoprecipitation or affinity
chromatography, or more recent and elaborate techniques
such as screening of protein or lipid arrays [64–67].
B cell and immunoglobulin repertoires
Analysis of the CSF has great diagnostic value for
inflammatory diseases of the central nervous system, since
CSF samples are readily available. In particular, intrathecal
antibody production is widely used in the diagnosis of MS.
Since its first description in 1942 [68], it is known that CSF
antibodies can be visualized as distinct bands in isoelectric
focusing gels, the OCBs. OCBs are composed of a limited
number of Ig species. The OCB antibodies belong
predominantly to the complement-activating IgG1 family.
They have undergone affinity maturation as evident from
extensive somatic hypermutation (SHM). Their pattern is
typical for each individual patient, and they may persist for
very long periods of time, even during immunosuppressive
therapy. Altogether, these observations suggest an antigen-
driven B cell response. Although it has long been known
that the OCBs are synthesized intrathecally, it was
unknown whether the OCB-producing cells reside in the
CSF, in the brain parenchyma, or in the ectopic B cell
follicles in the cerebral meninges. Detailed analyses of the
Ig transcript repertoires from CSF-resident B cells revealed
clonal restrictions (“oligoclonality”) and a high degree of
SHM [59, 69–73]. Therefore, it was assumed that these B
cells might produce the OCBs, but this assumption has
never been proven. None of the previously published
studies attempted to link the two data sets by analyzing
both Ig proteins and transcripts in parallel.
To analyze the antibody repertoires in MS, we developed
a new technique for comparing Ig repertoires at the Ig
transcript (B cell) and protein (antibody) levels (Fig. 4). We
created patient-specific IgG databases from diagnostic CSF
samples by analyzing the Ig transcripts of the B cells. In
parallel, we analyzed the Ig proteins directly by mass
spectrometry. In contrast to traditional analyses, which
compare germ line transcriptomes and proteomes, our
approach is based on the SHM and hypervariable V(D)J
recombination patterns, which are unique to each patient.
Thus, we preferentially analyzed “characteristic” peptides,
i.e., peptides which contain amino acids introduced by
SHM or V(D)J recombination. We analyzed four patients
by comparing their CSF Ig-proteomes and transcriptomes
and found that the CSF Ig-proteomes match to large extent
with the corresponding B cell Ig-transcriptomes. We
showed by two independent experiments that this alignment
is specific: First, we analyzed all peptides by tandem mass
spectrometry. Although this technique usually does not
yield results for all peptides tested, we could show for some
characteristic peptides that they are indeed patient-specific.
Second, we tested the specificity of our alignments by
comparing the proteomes of a patient not only to the
“correct” transcriptome, i.e., the transcriptome of the very
same patient, but also the transcriptome of “incorrect”, i.e.,
other, patients. Both experiments revealed that our align-
ments were correct. This high concordance demonstrates
that the B lineage cells contained in the CSF are indeed a
source of the Ig OCBs [54].
A still open question regards the target antigens of
OCBs. Several B cell antigens have been described that are
Fig. 4 Comparison of B cell transcriptome and immunoglobulin
proteome from the cerebrospinal fluid (CSF) of multiple sclerosis
patients by molecular cloning and mass spectrometry. We found
strong overlaps between the transcriptomes and proteomes. This
provides evidence that CSF-resident B cells are capable to synthesize
the IgGs which constitute the OCBs
474 Semin Immunopathol (2009) 31:467–477recognized by (auto) antibodies from serum or CSF of MS
patients [51], but none of them could be attributed to
OCBs. Interestingly, there seems to be an obvious contra-
diction: On one hand, the OCB antibodies are quantitatively
expanded Ig populations, carry extensive SHM, and
preferentially belong to the IgG1 family. This provides
strong evidence that the producing B cells had long-lasting
contact with their antigens. On the other hand, the OCB are
soluble antibodies that are present in high concentrations in
the CSF. This means that they are not absorbed by their
antigens and/or that their antigens are present in very low
concentrations. If so, why are these antigens not removed
by various antibody-dependent clearance mechanisms? Our
technology for analyzing OCBs may help to address this
question. If the paired heavy and light chains from
individual bands could be identified, then the paired Ig
chains can be expressed recombinantly and used for antigen
searches. Because the antibodies have undergone affinity
maturation, their affinities are presumably high. This will
allow isolation of the antigens by affinity chromatography
and their analysis by mass spectrometry. However, the
abovementioned correlation is technically not trivial,
because the OCBs are always embedded in a pool of
polyclonal background of many non-expanded antibodies.
Therefore, such an approach would require further Ig
purification by 2-D electrophoresis and high-performance
liquid chromatography. Its advantage, however, is clear: It
focuses directly on OCB proteins. In contrast, the more
traditional analysis of antibodies produced by single B cells
does not reveal whether the antibodies belong to OCB.
Outlook
The new experimental tools that we described here will
advance our knowledge of the immunopathogenesis of MS
and other neuroimmunological diseases. Moreover, they
will help to identify new diagnostic biomarkers, e.g., for
identifying disease subtypes and—perhaps—new pathoge-
netic syndromes. Last but not least, the new techniques
have the potential eventually to improve our therapeutic
options, e.g., by helping to design “individualized” selec-
tive immunotherapies [74].
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